NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
Clinical Trials
9 trialsNCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT03661723 2024-09-19
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT06283927 2024-02-28
RECSUR
Erasmus Medical Center
Recruiting
NCT06093165 2023-10-23
REMIT
Rigshospitalet, Denmark
Phase NA Not yet recruiting
NCT01469247 2022-10-20
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
M.D. Anderson Cancer Center
Phase 1/2 Completed